Establishment Labs (NASDAQ:ESTA) Sets New 12-Month High – Time to Buy?

Establishment Labs Holdings Inc. (NASDAQ:ESTA) hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $96.99 and last traded at $95.65, with a volume of 636985 shares trading hands. The stock had previously closed at $93.42.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. BTIG Research reissued a “buy” rating on shares of Establishment Labs in a report on Monday, July 13th. TD Cowen restated a “buy” rating on shares of Establishment Labs in a report on Monday, June 8th. Wall Street Zen downgraded shares of Establishment Labs from a “buy” rating to a “hold” rating in a research report on Saturday, March 28th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Establishment Labs in a research note on Wednesday, June 24th. Finally, Mizuho increased their price target on Establishment Labs from $100.00 to $105.00 and gave the company an “outperform” rating in a report on Wednesday, July 15th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Establishment Labs presently has a consensus rating of “Moderate Buy” and an average target price of $90.43.

Establishment Labs Trading Up 2.4%

The stock has a market capitalization of $2.81 billion, a PE ratio of -64.19 and a beta of 1.06. The stock’s 50 day moving average price is $81.12 and its 200-day moving average price is $72.28. The company has a quick ratio of 1.91, a current ratio of 2.96 and a debt-to-equity ratio of 16.82.

Establishment Labs (NASDAQ:ESTA) last released its earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.10). The firm had revenue of $59.88 million for the quarter, compared to analysts’ expectations of $57.40 million. Establishment Labs had a negative net margin of 19.05% and a negative return on equity of 218.77%. The firm’s quarterly revenue was up 44.7% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.70) EPS. On average, sell-side analysts expect that Establishment Labs Holdings Inc. will post -1.07 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Quiros Juan Jose Chacon sold 105,000 shares of the business’s stock in a transaction dated Wednesday, May 6th. The stock was sold at an average price of $75.42, for a total value of $7,919,100.00. Following the transaction, the director directly owned 927,504 shares in the company, valued at $69,952,351.68. The trade was a 10.17% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 255,000 shares of company stock worth $18,144,896 over the last quarter. 9.99% of the stock is owned by company insiders.

Institutional Trading of Establishment Labs

Institutional investors have recently made changes to their positions in the business. KBC Group NV bought a new stake in Establishment Labs during the 1st quarter valued at approximately $28,000. Quarry LP bought a new position in Establishment Labs in the 3rd quarter worth approximately $34,000. Kestra Advisory Services LLC purchased a new stake in Establishment Labs during the 4th quarter valued at approximately $47,000. Osaic Holdings Inc. grew its holdings in Establishment Labs by 900.0% during the 2nd quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock valued at $85,000 after buying an additional 1,800 shares in the last quarter. Finally, MV Capital Management Inc. bought a new stake in shares of Establishment Labs during the fourth quarter valued at approximately $146,000. Hedge funds and other institutional investors own 72.91% of the company’s stock.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.